Incannex Healthcare Inc. (IXHL) Tuesday reported positive data from its Phase 2 study of PSX-001 a psilocybin-assisted psychotherapy treatment for generalised anxiety disorder.
In the study, participants with generalised anxiety disorder were randomized to receive either PSX-00 or placebo. Results from the study showed that patients treated with PSX-001 achieved an average 12.8-point reduction in HAM-A (Hamilton Anxiety Rating Scale) scores from baseline, compared to a 3.6-point reduction in the placebo group. In 44.1% of patients, a 50% reduction in HAM-A score was observed, 4 times higher than the placebo group. Twenty seven percent of patients receiving PSX-001 achieved full disease remission, five times higher than placebo.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.